Unknown PHASE4 INTERVENTIONAL 2-arm NCT02477852

The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis

The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis Patients

Sponsor: Beijing Chest Hospital

Conditions Tuberculosis, Spinal

Interventions Ethambutol Isoniazid Pyrazinamide Rifampicin

Updated 7 times since 2017 Last updated: Jun 22, 2015 Started: Apr 30, 2015 Primary completion: Dec 31, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02477852, this PHASE4 trial focuses on Tuberculosis, Spinal and remains ongoing. Sponsored by Beijing Chest Hospital, it has been updated 7 times since 2015, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Chest Hospital
Beijing Municipal Science & Technology Commission

Data source: Beijing Chest Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China